Form 4: Nurix Therapeutics Director Judith A. Reinsdorf Granted Stock Options
SEC Form 4 Filing
Director Judith A. Reinsdorf of Nurix Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock on May 20, 2024.
Summary
- Judith A. Reinsdorf, a director of Nurix Therapeutics, Inc., was granted stock options on May 20, 2024.
- The options allow her to purchase 25,000 shares of Nurix Therapeutics common stock at an exercise price of $16.19 per share.
- The stock options vest fully on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, contingent upon her continued service to the Issuer.
- The options expire on May 19, 2034.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for directors.
Positives
- The grant of stock options to a director aligns her interests with those of the shareholders.
- The vesting schedule incentivizes continued service to the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation. This grant is typical for directors of publicly traded companies.
Comparison to Industry Standards
- Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
- The size of the grant (25,000 shares) and the vesting schedule (vesting within one year) appear to be within typical ranges for companies of Nurix Therapeutics' size and stage.
- Comparable companies such as Arvinas or Relay Therapeutics also utilize stock options as part of their director compensation packages.
Stakeholder Impact
- The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 05/20/2024 | Date of the stock option grant. |
| 05/20/2025 | Date of full vesting of the stock options (or earlier at the next annual meeting). |
| 05/19/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.